By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novogen Limited 

140 Wicks Road

North Ryde    NSW 2113  Australia
Phone: 203-327-1188 Fax: 203-327-0011



Company News
Novogen Limited (NVGN) Engages Contract Research Organisation To Conduct Cantrixil Phase 1 Clinical Trial 11/24/2015 6:17:35 AM
Novogen Limited (NVGN) Patent Covering Cantrixil And Trilexium Accepted In Australia 11/12/2015 7:41:57 AM
Novogen Limited (NVGN) Release: Preclinical Studies Justify Mode Of Delivery And Dosing Regimen For Anisina 11/11/2015 6:55:10 AM
Novogen Limited (NVGN) Announces The Outcome Of A Comprehensive Science Review 8/31/2015 7:32:52 AM
Newly Appointed Acting CEO Outlines Immediate Plans For Novogen Limited (NVGN) 7/31/2015 8:56:29 AM
Novogen Limited (NVGN) Appoints Iain Ross As Acting CEO And Re-Appoints Him To The Board 7/22/2015 11:50:45 AM
Novogen Limited (NVGN) Release: Anisina Receives Orphan Drug Designation From FDA For Neuroblastoma 7/16/2015 11:47:13 AM
Novogen Limited (NVGN) Release: Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness In Childhood Cancer 7/14/2015 6:54:56 AM
Novogen Limited (NVGN) Announces the Chairman's Address At The Company's General Meeting 6/24/2015 11:35:11 AM Publishes New SNNLive Video Interview With Novogen Limited (NVGN) 6/17/2015 2:24:12 PM